Table 2:
Process of Care and Outcomes Measures in Patients Predicted to Have High-Risk CAD
| High Risk (≥50%) N=301 |
Non-High Risk (<50%) N=4207 |
OR [HR] (95% CI)* | p-value† | High Risk (≥70%) N=111 |
Non-High Risk (<70%) N=4409 |
OR [HR] (95% CI)* | p-value‡ | |
|---|---|---|---|---|---|---|---|---|
| Processes of Care | ||||||||
| ICA within 90 days after CTA§ | 190 (63.1%) | 338 (8.0%) | 19.6 (15.1, 25.4) |
<0.0001 | 82 (73.9%) | 452 (10.3%) | 24.8 (16.0, 38.2) |
<0.0001 |
| PCI (90 days)§ | 69 (22.9%) | 143 (3.4%) | 8.5 (6.2, 11.6) |
<0.0001 | 30 (27.0%) | 183 (4.2%) | 8.6 (5.5, 13.3) |
<0.0001 |
| CABG (90 days)‖ | 46 (15.3%) | 16 (0.4%) | 47.3 (26.4, 84.6) |
<0.0001 | 29 (26.1%) | 33 (0.7%) | 46.9 (27.2, 80.8) |
<0.0001 |
| PCI/CABG (90 days)§ | 115 (38.2%) | 158 (3.8%) | 15.8 (12.0, 21.0) |
<0.0001 | 58 (52.3%) | 216 (4.9%) | 21.2 (14.3, 31.6) |
<0.0001 |
| Outcomes | ||||||||
| CV Death/MI# | 8 (2.7%) | 52 (1.2%) | 2.11 (1.00, 4.44) |
0.0447 | 4 (3.6%) | 56 (1.3%) | 2.78 (1.01, 7.67) |
0.0391 |
| CV Death/MI/UA# | 26 (8.6%) | 84 (2.0%) | 4.47 (2.88, 6.94) |
<0.0001 | 13 (11.7%) | 97 (2.2%) | 5.74 (3.22, 10.24) |
<0.0001 |
| All Cause Death/MI# | 11 (3.7%) | 77 (1.8%) | 1.96 (1.04, 3.69) |
0.0334 | 4 (3.6%) | 84 (1.9%) | 1.86 (0.68, 5.08) |
0.2161 |
| All Cause Death/MI/UAH# | 29 (9.6%) | 109 (2.6%) | 3.85 (2.56, 5.80) |
<0.0001 | 13 (11.7%) | 125 (2.8%) | 4.48 (2.53, 7.93) |
<0.0001 |
| UAH (CEC)# | 19 (6.3%) | 34 (0.8%) | 8.05 (4.59, 14.11) |
<0.0001 | 9 (8.1%) | 44 (1.0%) | 8.52 (4.16, 17.44) |
<0.0001 |
*
Odds ratio (95% CI) listed for Process of Care, hazard ratios (95% CI) for Outcomes.
†
Comparing High Risk vs. Non-High Risk (50% criteria).
‡
Comparing High Risk vs. Non-High Risk (70% criteria).
§
Chi-square test. ‖Fisher’s exact test.
#
Log-rank test.
CV = cardiovascular, CTA = computed tomographic angiography, CABG = coronary artery bypass graft surgery, ICA = invasive coronary angiography, MI = myocardial infarction, PCI = percutaneous coronary intervention, UAH = unstable angina hospitalization.